Summary:
- The U.S. Food and Drug Administration (FDA) has accepted Bristol-Myers Squibb's new drug application for iberdomide, a treatment for patients with relapsed or refractory multiple myeloma.
- Multiple myeloma is a type of blood cancer that affects the plasma cells, which are responsible for producing antibodies. Relapsed or refractory multiple myeloma refers to the disease returning or not responding to previous treatments.
- Iberdomide is a novel immunomodulatory drug that works by stimulating the immune system to attack and kill the cancer cells. This new treatment option could provide hope for patients with this challenging form of cancer.